DULOXETINE Drug Patent Profile
✉ Email this page to a colleague
When do Duloxetine patents expire, and when can generic versions of Duloxetine launch?
Duloxetine is a drug marketed by Actavis Elizabeth, Adaptis, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Almatica, Apotex, Aurobindo Pharma Ltd, Breckenridge, Cspc Ouyi, Hetero Labs Ltd Iii, Inventia, Lupin, Macleods Pharms Ltd, Ph Health, Prinston Inc, Qingdao Baheal Pharm, Sun Pharm, Sunshine, Teva Pharms Usa, Torrent, Yaopharma Co Ltd, Zydus Hlthcare, and Zydus Pharms. and is included in twenty-four NDAs.
The generic ingredient in DULOXETINE is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Duloxetine
A generic version of DULOXETINE was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11th, 2013.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DULOXETINE?
- What are the global sales for DULOXETINE?
- What is Average Wholesale Price for DULOXETINE?
Summary for DULOXETINE
| US Patents: | 0 |
| Applicants: | 24 |
| NDAs: | 24 |
| Drug Prices: | Drug price information for DULOXETINE |
| Drug Sales Revenues: | Drug sales revenues for DULOXETINE |
| What excipients (inactive ingredients) are in DULOXETINE? | DULOXETINE excipients list |
| DailyMed Link: | DULOXETINE at DailyMed |
US Patents and Regulatory Information for DULOXETINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Hlthcare | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 090739-004 | Apr 18, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Lupin | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 090694-003 | Dec 11, 2013 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Cspc Ouyi | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 211310-003 | Oct 16, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Prinston Inc | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 206653-001 | May 18, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sunshine | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 212328-003 | Feb 11, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Macleods Pharms Ltd | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 204815-003 | Mar 23, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
